ViMREX GmbH
ViMREX GmbH develops novel targeted therapies and preventive treatments for tumors, specifically focusing on diseases caused by human papillomaviruses (HPV).
Classification
Profile
Funding
Funding details not yet available.
Develops novel, targeted, and easy-to-use treatments and prevention methods for tumors, specifically those caused by human papillomaviruses (HPV).
Patients suffering from HPV-induced tumors and healthcare providers in the DACH region seeking advanced therapeutic solutions.
Product sales of proprietary pharmaceutical treatments and potential licensing agreements.
Direct sales through medical professionals and partnerships with healthcare institutions.
Advisory board chaired by Prof. Dr. Magnus von Knebel Doeberitz, leveraging academic expertise for strategic guidance.
Primary costs are driven by research and development of novel pharmaceutical approaches and medical expertise.
Proprietary medical IP, leadership by Dr. Elena-Sophie Prigge (MD, MBA), and academic advisory support.
Developing new approaches for tumor treatment and prevention, focusing on HPV-related diseases and targeted medication.
Sales-led engagement with healthcare providers and patient advocacy groups.
Competes in the oncology and HPV treatment space with a focus on novel, targeted, and user-friendly pharmaceutical solutions.
Limited effective treatments for HPV-induced tumors and the need for easier-to-apply, targeted therapeutic options.
- Accelerate B2B partnership pipeline - Identify 3-5 mid-size pharma firms with existing HPV-oncology portfolios and initiate “co-developme
Short-term - Focus on completing Phase II with clear efficacy endpoints; use data to negotiate milestone-rich licensing deals · Mid-term - If licensing partners are secured, shift R&D spend toward formulation optimisation and regulatory filing; leverage partner’s sale · Long-term - Consider dual-track: retain rights for niche markets (e.g., Europea
- Clinical data → Licensing power - Robust Phase II/III results will dramatically increase milestone & royalty valuations
- Primary source validation - All core facts (mission, leadership, trial status) come directly from ViMREX’s official website and the Europ
No investors recorded yet.